Deferred registration - Klear Bio Code: KLR003-Clin-004
This clinical trial, identified by the code KLR003-Clin-004, is an early-stage Phase I study run by Klear Bio. Phase I studies are usually the first step in testing a new treatment in people, focusing mainly on safety, dosage, and side effects. Currently, specific details about the exact condition being treated, the test medicine, and the study procedures have been temporarily delayed from public release. This 'deferred registration' has been officially reviewed and approved by the UK Health Research Authority (HRA), often to protect sensitive scientific data or patent timings. What is known right now is that the trial will involve adults aged between 18 and 65 years of all sexes. Full scientific and clinical details will be made publicly available on the UK trial registry as soon as the approved deferral expiry date arrives.
At a glance
What is this study about?
Clinical research follows strict phases to ensure safety, starting with Phase I trials. These early-stage trials are usually designed to evaluate how a new medicine behaves in the human body, whether it causes any unwanted side effects, and what dose is safe to use. This particular study, known as KLR003-Clin-004 and sponsored by Klear Bio, is one such Phase I trial.
At present, the detailed background and medical focus of this trial have not yet been made public. In the UK, the Health Research Authority (HRA) can grant permission to delay the public release of full study details—known as a 'deferred registration'. This commonly happens when researchers need to protect commercial secrets, intellectual property, or patent applications during early development, while still ensuring the research has undergone rigorous ethical and scientific checks.
Even though the public information is limited for now, the trial must follow all UK safety standards, clinical regulations, and ethical guidelines. Once the agreed deferral date passes, the full scientific background, the specific health condition, and the treatment being tested will be published on the registry so patients and doctors can read about the findings.
Key takeaways
- KLR003-Clin-004 is an early-stage Phase I trial sponsored by Klear Bio.
- Full details are temporarily deferred under approval from the UK Health Research Authority.
- The study involves adult participants aged 18 to 65 years of any sex.
- The trial still follows strict UK safety and ethical regulations despite the deferred listing.
- Complete information regarding the condition, treatment, and visits will be published once the deferral expires.
Who may be eligible?
Because the full study details are deferred, the complete list of who can and cannot join this trial has not yet been shared publicly. The main criteria currently available are that participants must be aged between 18 and 65 years, and the study is open to people of all genders.
In most Phase I trials, participants must meet specific health checks to ensure taking part is safe for them. Depending on the trial design, Phase I studies may seek either healthy volunteers or people living with a specific medical condition that the experimental drug hopes to treat.
Full inclusion and exclusion criteria—such as required medical history, routine test results, or medications that cannot be taken at the same time—will be revealed once the deferral period expires and the public registry is updated.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged between 18 and 65 years old.
- I am willing to participate in an early-stage (Phase I) clinical research study.
- I understand that full medical criteria will only be revealed once the official deferral ends.
- I am able to attend clinic visits for regular safety and health monitoring if accepted.
What does participation involve?
Because this study's full protocol is temporarily private, the exact schedule of clinic visits, tests, and treatments is not yet publicly known. Typically, taking part in a Phase I trial involves an initial screening visit where doctors check your health, blood tests, and heart readings to see if you can safely join. If eligible, participants usually receive the study medicine (by mouth, injection, or drip) and stay at a research clinic for close monitoring, followed by routine follow-up appointments. The exact length of the study and clinic visits will be clarified when the Health Research Authority publishes the full trial record.
Potential risks and benefits
Locations (1)
- The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry dateUnverified-, England
Common questions
What does 'deferred registration' mean?
It means the UK Health Research Authority has allowed the researchers to keep the full study details private for a limited time, usually to protect intellectual property or patent rights.
Is a trial with deferred details still safe?
Yes. The trial must still receive full ethical and regulatory approvals from UK authorities to ensure strict participant safety standards are met.
What is a Phase I trial?
A Phase I trial is an early-stage study that tests a new medicine in a small group of people to assess safety, safe dosage levels, and any side effects.
When will the full details be available?
The full scientific details, medical condition, and entry criteria will be added to the registry on or before the agreed deferral expiry date.
Can I sign up for this study right now?
Recruitment details are currently limited. You can check back on the clinical trial registry after the deferral expires or speak to your doctor about other available clinical trials.
How to find out more
Timothy P Reilly
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.